Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vistagen Therapeutics, Inc.VTGN · Entity 7955 | CHIEF FINANCIAL OFFICER | June 30, 2025 | July 01, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vistagen Therapeutics, Inc.
Report date June 30, 2025 · Filed July 01, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,801 |
Reported balance
After 2025-06-30 transaction · row 1
1 source rowRow 1 · 2025-06-30 · Grant · Acquired 6,617 · Balance 12,801 F1: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2025 Filed Jul 1, 2025 21:49 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 6,617 | $1.70 | $11,248.90 |
DisclosureSEC source: 0001415889-25-018751 · form4-07012025_090741.xml · nonDerivative · entry 1 Anderson Cynthia Lynn · CIK 0001989905 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,801 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:15 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001415889-25-018203 · form4-06252025_050607.xml · derivative · entry 1 Anderson Cynthia Lynn · CIK 0001989905 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the "Grant Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date. Read SEC document |
| December 31, 2024 Filed Jan 13, 2025 22:39 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 2,592 | $2.51 | $6,499.44 |
DisclosureSEC source: 0001415889-25-001396 · form4-01132025_100126.xml · nonDerivative · entry 1 Anderson Cynthia Lynn · CIK 0001989905 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,184 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's 2019 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 22:08 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantCommon Stock | 3,592 | $2.96 | $10,625.14 |
DisclosureSEC source: 0001415889-24-019024 · form4-07022024_100748.xml · nonDerivative · entry 1 Anderson Cynthia Lynn · CIK 0001989905 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,592 F1 · shares: Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended. Read SEC document |
| June 24, 2024 Filed Jun 27, 2024 01:30 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001415889-24-018277 · form4-06272024_010602.xml · derivative · entry 1 Anderson Cynthia Lynn · CIK 0001989905 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 24, 2024 (the "Vesting Start Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Vesting Start Date. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 17:09 UTC | Vistagen Therapeutics, Inc. VTGN · Entity 7955 | GrantStock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001415889-23-012532 · form4-08232023_050842.xml · derivative · entry 1 Anderson Cynthia Lynn · CIK 0001989905 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2033-08-21 F2 · price: The stock options were granted in connection with the Reporting Person's appointment as Chief Financial Officer and pursuant to the Issuer's 2019 Omnibus Equity Incentive Plan. F1 · derivative.exercise_date: 25% of the stock options vest on August 21, 2024 (the "Vesting Start Date") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.